EGFR and non-small cell lung carcinoma: <h4>Objectives</h4>Tyrosine kinase inhibitors (TKIs) are a standard care option in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation.